Cargando…

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma

Detalles Bibliográficos
Autores principales:	Wada, Yoshihiro, Tanoue, Kenichiro, Takahashi, Wataru, Eto, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2012
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708159/ https://www.ncbi.nlm.nih.gov/pubmed/26816712 http://dx.doi.org/10.3978/j.issn.2223-4683.2012.05.04

Ejemplares similares

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
por: Yoshimura, Akihiro, et al.
Publicado: (2020)

Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
por: Rassy, Elie, et al.
Publicado: (2020)

Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors
por: Cortes, Jorge, et al.
Publicado: (2018)

Towards new treatment options for renal cell carcinoma: development and clinical results of tivozanib, a selective VEGFR tyrosine kinase inhibitor
por: Eskens, Ferry ALM, et al.
Publicado: (2012)

Fasting plus tyrosine kinase inhibitors in cancer
por: Caffa, Irene, et al.
Publicado: (2015)

Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor
por: Zhang, Hailiang, et al.
Publicado: (2023)

Severe bleeding tendency caused by a rare complication of excessive fibrinolysis with disseminated intravascular coagulation in a 51-year-old Japanese man with prostate cancer: a case report
por: Wada, Yoshihiro, et al.
Publicado: (2012)

Third Generation Tyrosine Kinase Inhibitors and Their Development in Advanced Renal Cell Carcinoma
por: Bukowski, Ronald M.
Publicado: (2012)

Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
por: Vasudev, Naveen S., et al.
Publicado: (2011)

Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinoma—Future or the Past?
por: Michaelis, Jakob, et al.
Publicado: (2022)

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

Biomarkers for tyrosine kinase inhibitors in renal cell cancer
por: Coupe, Nicholas, et al.
Publicado: (2012)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors
por: Tahiri, Andliena, et al.
Publicado: (2022)

Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma
por: Sekino, Yohei, et al.
Publicado: (2022)

Complete Remission of Bone Metastases in Renal Cell Carcinoma with Nivolumab
por: Vuyyala, Sowjanya, et al.
Publicado: (2019)

Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma
por: Inoue, Takaaki, et al.
Publicado: (2012)

Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy
por: Aparicio, L. M. A., et al.
Publicado: (2017)

Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
por: Wu, Jialu, et al.
Publicado: (2020)

The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma
por: Buti, Sebastiano, et al.
Publicado: (2022)

Tyrosine Kinases in Cancer
por: Blau, Olga, et al.
Publicado: (2015)

MicroRNAs as predictive biomarkers of treatment response to tyrosine kinase inhibitors in hepatocellular carcinoma: how much is missing?
por: Gramantieri, Laura, et al.
Publicado: (2022)

Long-lasting complete remission in a patient with systemic metastases of recurrent breast cancer treated with cyclin-dependent kinases 4/6 inhibitors: a case report
por: Yoneto, Toshihiko, et al.
Publicado: (2023)

The Impact of Renal Impairment on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors
por: Zhang, Haoran, et al.
Publicado: (2020)

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases
por: Beuselinck, B, et al.
Publicado: (2012)

Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients
por: Tullemans, Bibian M. E., et al.
Publicado: (2018)

LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma
por: Naito, Sei, et al.
Publicado: (2017)

Comparison of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma with rhabdoid and sarcomatoid differentiations
por: Wang, Kun, et al.
Publicado: (2023)

The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma—successes and challenges
por: Oduah, Eziafa I., et al.
Publicado: (2022)

Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in  Clear - Cell Renal Cell Carcinoma (ccRCC)
por: Bielecka, Zofia F., et al.
Publicado: (2013)

Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma
por: Ishihara, Hiroki, et al.
Publicado: (2017)

PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors
por: Rosell, Rafael, et al.
Publicado: (2015)

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?
por: Tabbò, Fabrizio, et al.
Publicado: (2020)

Chronic Myeloid Leukemia in Children and Adolescents: The Achilles Heel of Oncogenesis and Tyrosine Kinase Inhibitors
por: Moschovi, Maria, et al.
Publicado: (2021)

Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma
por: Busch, Jonas, et al.
Publicado: (2011)

Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors
por: Cho, Daniel C
Publicado: (2013)

Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors
por: Janisch, Florian, et al.
Publicado: (2021)

Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor
por: Teishima, Jun, et al.
Publicado: (2021)

Prognostic significance of pseudocapsule status in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
por: Xi, Wei, et al.
Publicado: (2021)

PD-L1 expression in papillary renal cell carcinoma
por: Motoshima, Takanobu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_oqa6n2u2lds5s18glcjh9va5ui